title: [Guidelines on the use of methotrexate in psoriasis].
abstract: Psoriasis, a chronic multifactorial inflammatory disease that develops in genetically predisposed individuals, affects approximately 1.5% of the Spanish population. This disease has a negative impact on patients' quality of life, and long-term therapy is often required to control the symptoms. In addition to the classical systemic treatments (methotrexate, acitretin, cyclosporine, and ultraviolet light), the group of drugs known as biologics (etanercept, infliximab, adalimumab, and ustekinumab) provides the dermatologist with an expanded therapeutic armamentarium, thereby improving the likelihood of controlling psoriasis in patients with severe and/or extensive disease. Methotrexate, a classic antipsoriatic drug, is still very useful either as single-drug therapy or in combination with other systemic drugs, particularly as a rescue therapy or combined with biologics. This article aims to establish the role of methotrexate in the treatment of psoriasis. We considered it of interest to develop guidelines for using methotrexate in the management of psoriasis with a view to ensuring the safe and proper use of this drug in the management of psoriasis. This document was developed by consensus among members of the Psoriasis Group of the Spanish Academy of Dermatology and Venereology.
authors.affiliation: Hospital Universitario de Gran Canaria Doctor Negrín, Las Palmas de Gran Canaria, España. gcarrete@aedv.es
authors.forename: G
authors.initials: G
authors.lastname: Carretero
authors.forename: L
authors.initials: L
authors.lastname: Puig
authors.forename: L
authors.initials: L
authors.lastname: Dehesa
authors.forename: J M
authors.initials: JM
authors.lastname: Carrascosa
authors.forename: M
authors.initials: M
authors.lastname: Ribera
authors.forename: M
authors.initials: M
authors.lastname: Sánchez-Regaña
authors.forename: E
authors.initials: E
authors.lastname: Daudén
authors.forename: D
authors.initials: D
authors.lastname: Vidal
authors.forename: M
authors.initials: M
authors.lastname: Alsina
authors.forename: C
authors.initials: C
authors.lastname: Muñoz-Santos
authors.forename: J L
authors.initials: JL
authors.lastname: López-Estebaranz
authors.forename: J
authors.initials: J
authors.lastname: Notario
authors.forename: C
authors.initials: C
authors.lastname: Ferrandiz
authors.forename: F
authors.initials: F
authors.lastname: Vanaclocha
authors.forename: M
authors.initials: M
authors.lastname: García-Bustinduy
authors.forename: R
authors.initials: R
authors.lastname: Taberner
authors.forename: I
authors.initials: I
authors.lastname: Belinchón
authors.forename: J
authors.initials: J
authors.lastname: Sánchez-Carazo
authors.forename: J C
authors.initials: JC
authors.lastname: Moreno
mesh_terms: D056486:Chemical and Drug Induced Liver Injury / Q000209:etiology; D006801:Humans; D007166:Immunosuppressive Agents / Q000009:adverse effects / Q000627:therapeutic use*; D008727:Methotrexate / Q000009:adverse effects / Q000627:therapeutic use*; D011565:Psoriasis / Q000188:drug therapy*; D011996:Records
chemical_list: D007166:Immunosuppressive Agents; D008727:Methotrexate